乔治临床( George Clinical ) China has appointed a new General Manager to lead its growing operation in China as it seeks to provide a stronger platform for delivering clinical trials across the Asian region.
A recognised healthcare professional, Philip Gregory has 25 years senior management experience in pharmaceutical, device and biotechnology industries.
Prior to taking up the role with 乔治临床( George Clinical ) China he was the Regional Director Asia-Pacific for Pharmaxis Ltd based in Shanghai, and earlier in his career, he worked in Japan, the USA and Europe.
He will now be based at the 乔治临床( George Clinical ) China headquarters in Beijing.
A division of The George Institute for Global Health, 乔治临床( George Clinical ) is a world-class provider of a full range of premium clinical trial development and management services. 乔治临床( George Clinical ) has more than ten years experience in conducting world-class clinical trials and has played a role in some of the largest and most important global studies in this period.
According to 乔治临床( George Clinical ) Chief Executive Officer Dr Marisa Petersen, the appointment of Mr Gregory signals the organisation’s focus on developing both regional and global business – China is key to both of these. 乔治临床( George Clinical ) has a unique position in the outsourcing market, combining scientific expertise and trial leadership from some of the best research leaders in the world together with high quality, full service operations for the delivery of clinical trials across the Asia-Pacific region.
In addition to Beijing, 乔治临床( George Clinical ) also has offices in Bangalore and Hyderabad in India, Hong Kong, Malaysia and Australia.